GlobeNewswire Inc.··NaEyePoint Advances Wet AMD Pipeline With Third Positive Safety Review
EyePoint achieves third consecutive positive DSMC recommendation for wet AMD Phase 3 trials, with topline data expected mid-2026. Company presenting at May-June investor conferences.
EYPTPhase 3 trialsbiopharmaceutical